NTRK G595R: Solvent-Front Resistance to TRK Inhibitors

NTRK gene fusions drive oncogenesis across diverse tumor types, and the first-generation TRK inhibitors larotrectinib and entrectinib have delivered durable responses in many patients. But acquired resistance emerges in most cases, and the G595R mutation in the TRKA kinase domain stands out as one of the most common on-target mechanisms. Understanding why this single amino acid substitution abolishes first-generation inhibitor activity—and how second-generation agents overcome it—illustrates the interplay between structure, binding kinetics, and rational drug design.

NTRK Fusions and the Clinical Success of First-Generation Inhibitors

Gene fusions involving NTRK1, NTRK2, or NTRK3 produce constitutively active TRK kinases that drive cell proliferation and survival. These fusions occur at low frequency across many adult and pediatric cancers but define the oncogenic driver in certain contexts. Larotrectinib and entrectinib, both ATP-competitive type I kinase inhibitors, bind the active conformation of TRK kinases with high affinity and selectivity. Clinical trials demonstrated objective response rates exceeding 75% in TRK fusion-positive tumors, leading to tumor-agnostic approvals.

Despite these initial responses, progression-free survival curves show that most patients develop resistance within one to two years. Tumor sequencing at progression frequently reveals secondary mutations in the NTRK kinase domain, with G595R in TRKA emerging as a recurrent solvent-front substitution.

The Structural Role of G595 and the G595R Substitution

Glycine 595 in TRKA sits at the solvent-exposed front of the ATP-binding pocket, adjacent to the hinge region. This position is analogous to the gatekeeper residue plus one in many kinases, and glycine at this site provides minimal steric bulk, allowing first-generation inhibitors to occupy the pocket without clash. Larotrectinib and entrectinib both extend toward this region, forming favorable interactions in the wild-type enzyme.

Substitution of glycine with arginine introduces a long, positively charged side chain directly into the inhibitor binding site. The arginine guanidinium group creates steric hindrance that displaces the inhibitor and introduces electrostatic repulsion if the ligand carries proximal polar or aromatic groups. Biochemical assays show that G595R reduces larotrectinib binding affinity by more than 100-fold, rendering clinically achievable drug concentrations insufficient to suppress kinase activity.

The G595R mutation does not grossly destabilize the kinase fold or eliminate ATP binding; rather, it selectively disrupts inhibitor recognition while preserving catalytic function. This selective resistance explains why tumors harboring G595R continue to depend on TRK signaling and remain sensitive to appropriately designed next-generation inhibitors.

Second-Generation TRK Inhibitors: Selitrectinib and the Macrocyclic Strategy

Selitrectinib (also known as LOXO-195 and BAY-2731954) represents the lead second-generation TRK inhibitor designed explicitly to overcome solvent-front mutations including G595R. Selitrectinib incorporates a macrocyclic scaffold that rigidifies the inhibitor, reducing entropic penalty upon binding and enabling a binding pose that avoids clash with the arginine side chain. The macrocycle also presents different vectors for kinase interaction, exploiting hydrophobic pockets that remain accessible even when G595 is mutated.

Preclinical data demonstrate that selitrectinib retains nanomolar potency against TRKA G595R, and clinical case reports show objective tumor regressions in patients who progressed on larotrectinib with documented G595R mutations. The compound also covers other common resistance mutations such as G667C and F589L, providing broad second-line activity.

The rational design of selitrectinib relied on co-crystal structures of TRK kinases with first-generation inhibitors, computational modeling of resistance mutations, and iterative medicinal chemistry. This structure-guided approach exemplifies how resistance mechanisms inform inhibitor optimization.

Mutation-Aware Docking for Resistance Prediction and Inhibitor Design

Traditional docking workflows score ligands against a single wild-type receptor structure, which fails to capture the impact of resistance mutations. Mutation-aware docking introduces the altered residue computationally, relaxes the local environment, and re-evaluates ligand binding. This approach surfaces potential resistance liabilities early in the design cycle and guides the selection of scaffolds with retained activity against mutant kinases.

For NTRK programs, mutation-aware docking can model G595R, G667C, and other known resistance sites to predict which chemotypes will remain effective. Comparing docking scores and binding poses between wild-type and G595R mutant structures highlights steric clashes and lost interactions, providing a quantitative rationale for scaffold modifications. Selitrectinib's success validates this paradigm: the macrocyclic core avoids the G595R side chain, a feature that could have been anticipated—and prioritized—using mutation-aware modeling.

Liganx integrates mutation-aware docking directly into the design workflow. Users can introduce resistance mutations in the Studio, compare binding predictions, and iterate on ligand structures without switching tools. This capability is especially valuable for kinase targets where resistance mutations cluster in predictable hotspots. Our mutation docking guide walks through the technical setup and interpretation of results for common resistance scenarios.

Clinical Implications and Future Directions

The G595R experience in TRK-positive cancers reinforces several lessons for precision oncology. First, on-target resistance is not a failure of the target but a consequence of selective pressure; tumors remain dependent on the driver kinase. Second, structure-based understanding of resistance mechanisms enables rational design of next-generation agents, compressing the timeline from resistance detection to clinical solution. Third, preemptive modeling of likely resistance mutations can inform first-generation inhibitor design, potentially delaying resistance or enabling combination strategies.

Ongoing questions include whether upfront combinations of first- and second-generation inhibitors can prevent G595R emergence, and whether third-generation agents will be needed as selitrectinib resistance develops. Tumor heterogeneity and polyclonal resistance—where multiple NTRK mutations coexist—add further complexity. Mutation-aware computational tools will play an increasing role in navigating this evolving landscape, supporting both drug discovery and clinical decision-making.

Conclusion

The NTRK G595R mutation exemplifies solvent-front kinase resistance: a single substitution that selectively disrupts inhibitor binding while sparing kinase function. Larotrectinib and entrectinib, despite their clinical success, cannot accommodate the bulky arginine side chain. Selitrectinib overcomes this liability through macrocyclic constraint and alternative binding geometry, restoring TRK inhibition in resistant tumors. Mutation-aware docking provides a computational framework to anticipate and address such resistance mechanisms, accelerating the design of more resilient kinase inhibitors. As resistance genotypes accumulate, integrating structural modeling into the drug development pipeline will be essential for staying ahead of tumor evolution.

References

• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. DOI: 10.1056/NEJMoa1714448
• Russo M, Misale S, Wei G, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6(1):36–44. DOI: 10.1158/2159-8290.CD-15-0940
• Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–972. DOI: 10.1158/2159-8290.CD-17-0507
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. DOI: 10.1038/s41571-018-0113-0